The Leadership Team


Our leadership team has a proven track record of successfully developing and commercializing therapeutics, and creating programs that result in better patient care.  They’ve also driven shareholder value, and built organizations into employers of choice.

Gregory J. Flesher | Chief Executive Officer


Mr. Flesher has served as Chief Executive Officer and director since July 2015. He is a pharmaceutical industry executive with more than 20 years of experience developing and commercializing new medicines. Previously he served as the Chief Business Officer at Avanir Pharmaceuticals, Inc. (acquired by Otsuka Pharmaceuticals for $3.5 billion). Mr. Flesher’s industry tenure includes roles across clinical development, sales and marketing, as well as corporate and business development at Avanir, InterMune, Amgen, and Eli Lilly and Company. During his industry tenure, Mr. Flesher has participated in several drug development programs resulting in multiple product approvals and successful launches in the U.S. and Europe. Mr. Flesher earned his B.S. in Biology from Purdue University and studied Biochemistry and Molecular Biology at Indiana University School of Medicine.

Christine G. Ocampo | Chief Financial and Compliance Officer


Ms. Ocampo has served as Chief Financial Officer since July 2015. She is responsible for leading OticPharma’s accounting, corporate finance, human resources, and compliance functions. Prior to joining the company, she served as vice president of finance and chief accounting officer for Avanir Pharmaceuticals, Inc. (acquired by Otsuka Pharmaceuticals). Former leadership roles include senior vice president and chief financial officer for Cardiogenesis Corporation, a medical device maker. Ms. Ocampo began her career in finance as an auditor at Ernst & Young, LLP. Ms. Ocampo graduated with a Bachelor of Science in Accounting from Seattle University and became a licensed Certified Public Accountant in 1996.

Catherine C. Turkel | Chief Development Officer


Dr. Turkel has served as Chief Development Officer since November 2015. She is responsible for leading OticPharma’s preclinical, clinical, regulatory, quality assurance and CMC development functions. Dr. Turkel has more than 30 years of combined clinical practice and drug development experience, including senior roles across clinical development, medical affairs, and global regulatory affairs. She has successfully led global development project teams resulting in multiple registrations of new drug treatments. Prior to joining the company, she served as Vice President, Neurology, Urology & Pain at Allergan. Other former leadership roles were at Cypros Pharmaceutical Corp., IVAC Corp., California Clinical Trials, and Siemens Infusions Systems. Dr. Turkel holds a Doctor of Pharmacy from the University of the Pacific, an MBA from the University of California, Irvine, and a Doctor of Philosophy in Business (Organization & Management) from Capella University.